EMA and EORTC workshop: How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions?: materials are now available

The European Medicines Agency (EMA) and the European Organisation for Research and Treatment of Cancer (EORTC) jointly organised a workshop on how patient-reported outcomes (PRO) as well as health-related quality of life (HRQoL) data can inform regulatory decisions (please see the draft agenda attached). This workshop brought together international experts from academia, learned societies, patients, regulatory agencies, health technology assessment bodies, and industry. The video recording, ...